The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.
about
Anti-vascular endothelial growth factor for diabetic macular oedemaAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaNew Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic RetinopathySystematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)Insulin use and risk of diabetic macular edema in diabetes mellitus: a systemic review and meta-analysis of observational studiesEffect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema.Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysisImmediate effect of intravitreal injection of bevacizumab on intraocular pressure.Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.Clinical trials registries are under-utilized in the conduct of systematic reviews: a cross-sectional analysis.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Current treatments in diabetic macular oedema: systematic review and meta-analysisRanibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.Evolving strategies in the management of diabetic retinopathyComparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK.Clinical Characteristics of Patients with Newly Diagnosed Diabetic Macular Edema in Turkey: A Real-Life Registry Study-TURK-DEM.Treatments for macular oedema following central retinal vein occlusion: systematic review.Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema.The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs.Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.New insights into the management of diabetic retinopathy.NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression.Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational StudyTreatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections
P2860
Q24193083-9ED3227B-8B8B-46D0-B7D4-339CF5B657C8Q24202071-2CDE476C-4376-4525-AEC4-03A8CFB61703Q26765468-D5E4093E-0896-4F29-A831-4137ECE5180FQ26823985-3B62E963-B045-4E0E-89E6-193F3F7B1FF6Q27010850-A772DAEE-A91B-4A5A-B7C1-83C943CAEE8FQ33568545-0BEFBDCD-8C4D-4844-B7E7-C4EFEBFCAA95Q33830753-86BE229C-14E4-4106-857F-C2BFE124E3C6Q33910289-4D38718A-6E59-4841-A0A5-B4D25ABA7C7BQ33968693-EFA65D71-F9C8-4B71-B655-F2069BBB9308Q33995887-9500D7B2-89B1-4D79-A54C-038D81935A66Q34441631-822FF381-D869-4F35-ABBF-AA4D726E9829Q34558187-35194CA9-88A3-4F8F-8D7A-8F12EB169B92Q34606190-14ABC0C9-1981-4171-8AC1-EA780EA8EBA0Q34711043-4582F50C-9A2F-4DB6-8876-8D8C0EE63AFDQ34987495-D13C4FCF-F2EA-4FF1-9C34-91676779B713Q35067102-6F6CE1FD-80B6-4C7E-B44B-3D87758F9FD1Q35655005-5D893B55-EF6B-4393-92FB-D38A57F03238Q35975239-49A8AEE2-51E0-4E9E-BD71-1EBD756BBD46Q36111710-96210945-52C1-481C-883D-51423F3A1367Q36313962-89363287-20FD-459B-A098-6111D98AC316Q37590692-6CBE55E0-10A2-42E8-BBC3-A354E48C0560Q38174893-618ED651-755A-4A67-8E43-2CB88CEB162BQ38897856-742C138E-F0B5-424C-BBBB-2E33722A6D2AQ39867113-2BADAA1C-D475-4C0B-A743-B02D30403314Q42864970-30658F2D-5BC7-434F-8CCD-D74F5DDA3A3DQ47911906-4C12320E-9434-40FD-A40B-FF89CFE00395Q58804239-72B511A4-1F31-4D46-86E1-027A28F6C460Q58841511-A8EFBD39-D92E-4051-AC39-0847871E19E1
P2860
The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The relative clinical effectiv ...... arison in a systematic review.
@ast
The relative clinical effectiv ...... arison in a systematic review.
@en
The relative clinical effectiv ...... arison in a systematic review.
@nl
type
label
The relative clinical effectiv ...... arison in a systematic review.
@ast
The relative clinical effectiv ...... arison in a systematic review.
@en
The relative clinical effectiv ...... arison in a systematic review.
@nl
prefLabel
The relative clinical effectiv ...... arison in a systematic review.
@ast
The relative clinical effectiv ...... arison in a systematic review.
@en
The relative clinical effectiv ...... arison in a systematic review.
@nl
P2093
P2860
P921
P356
P1433
P1476
The relative clinical effectiv ...... arison in a systematic review.
@en
P2093
Deepson Shyangdan
Norman Waugh
Pamela Royle
P2860
P356
10.1136/BMJ.E5182
P407
P5008
P577
2012-08-13T00:00:00Z